Endologix (ELGX) Posts Q2 Loss of $0.28/Share; Lowers Outlook

Endologix (NASDAQ: ELGX) reported Q2 EPS of ($0.28), $0.13 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $44.7 million versus the consensus estimate of $44.45 million.

GUIDANCE:

Endologix sees FY2018 revenue of $145-155 million, versus prior of $170-$180 million and the consensus of $175.6 million. The Company now expects 2018 GAAP loss per share in the range of $(1.04) to $(1.12), compared to the previous range of $(0.89) to $(0.95)

For earnings history and earnings-related data on Endologix (ELGX) click here.

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Goldman Sachs Upgrades Drax Group Plc. (DRX:LN) (DRXGY) to Buy
• Morgan Stanley Upgrades Mitsubishi Chemical Holdings (4188:JP) (MTLHY) to Overweight